Canada

BetterLife Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

BetterLife Secures Mitacs Funding in Collaboration with Carleton University Research Team for TD-0148A Preclinical Depression Studies

Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide

Therapeutic Area: Psychiatry/Psychology Product Name: TD-0148A

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Carleton University

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 24, 2021

Details:

TD-0148A is a second-generation lysergic acid diethylamide (“LSD”) derivative molecule that BetterLife believes will mimic the projected therapeutic potential of LSD without causing the undesirable psychoactive dissociative side effects, such as hallucinations.

Revive Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics

Lead Product(s): Psilocybine

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: University of Health Sciences Antigua

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 17, 2021

Details:

Development of a Psychedelic treatment center in Antigua and Barbuda using Revive’s novel formulations and delivery forms of psychedelics, including its proprietary psilocybin oral-thin film product to treat mental health and substance abuse disorders.